CAR-T Global CDMO Services

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Introduction

The advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.

Needs of CDMO Services for CAR-T Development

The biopharmaceutical industry has witnessed a significant evolution in recent years, characterized by the increasing complexity of therapeutic molecules and accelerated timelines. The demand for CAR-T cell therapies has surged due to their potential to provide targeted and personalized treatment for various cancers. Thus, CDMO companies face the dual challenge of ensuring the highest quality standards while meeting accelerated timelines.

Diversification and Complexity

Historically, CDMO projects focused primarily on simpler molecules. However, in recent years, there has been a marked shift towards more complex molecule formats, including chimeric antigen receptor (CAR) T cells. This complexity requires a higher level of technical competence.

Quality Commitments

Maintaining the highest quality standards is non-negotiable. Strict adherence to Good Manufacturing Practices (GMP) for the development and supply of materials for toxicology studies is critical. Quality assurance must permeate each stage of the development and manufacturing process, from the selection of raw materials to the testing of the final product.

Time pressure

The biopharmaceutical industry is driven by intense market competition, regulatory requirements, and the need to maintain patent exclusivity. As a result, customers expect not only shorter, but also reliable schedules. To minimize development costs, meet patient needs, and meet investor expectations, an accelerated timeline is critical.

Our Global CDMO Services for CAR-T

Creative Biolabs has built a reputation for delivering end-to-end CDMO services tailored to the unique needs of CAR-T cell therapies. Our services encompass every stage of the development and manufacturing process, ensuring a seamless transition from research to clinical and commercial stages.

Comprehensive Service Offerings

Process Development

Our expertise in process development ensures that CAR-T therapies are scalable and compliant with regulatory requirements. We utilize cutting-edge technologies to optimize cell culture conditions and purification methods, focusing on reproducibility and scalability.

Analytical Development

Our in-house analytical capabilities enable rigorous assay development and quality control, ensuring that all CAR-T products meet the highest standards of safety, potency, and purity.

Global CDMO Services for Plasmid

We offer a range of plasmid services, from research grade to GMP-grade plasmid DNA. These services are designed to support various stages of CAR-T development, offering flexibility and reliability.

Global CDMO Services for CAR Viral Vector

Viral vectors are crucial for CAR-T cell engineering. We offer research-grade, GMP-like, and GMP-grade viral vector production, including CGMP AAV, lentivirus, and retrovirus production. Our viral vector services ensure high purity, potency, and safety.

IVT RNA and LNP Manufacturing for CAR Cells

Our mRNA services range from research grade to GMP grade, including lipid nanoparticle encapsulation. This service is crucial for CAR-T cell modification and engineering.

CAR Viral Vector Packaging Services

Creative Biolabs provides comprehensive viral packing services for CART projects, including the production of research-grade viruses, GMP-like viruses, and cGMP-grade viruses such as AAV, lentivirus, and retrovirus.

Global CDMO Services for CAR Cells

We offer various grades of CAR cell production, including IIT grade, IND grade, ensuring that each stage of development is adequately supported.

Highlights of Our Global CDMO Services for CAR-T

Collaboration and Transparency

Our approach is highly collaborative and transparent. Clients are invited on-site to work alongside our team, fostering a deeper understanding of the project and enhancing the overall development process.

Quality by Design

Our commitment to quality is ingrained in our ‘Quality by Design’ approach. Process optimization, design of experiments, and rigorous quality control measures ensure that every CAR-T product meets benchmark standards.

Global Reach

With facilities across the globe, Creative Biolabs offers unparalleled flexibility and accessibility. Our services are able to support customers in different regions and provide consistent and high quality CDMO services worldwide.

Frequently Asked Questions

Q1: How does Creative Biolabs ensure the quality of CAR-T products?

A1: We employ a "Quality by Design" approach, focusing on process optimization, rigorous quality control, and strict adherence to GMP standards. Our internal analysis further ensures the safety, efficacy, and purity of the highest standard.

Q2: How do you handle the complexity of CAR-T projects?

A2: Our extensive experience and technological capabilities enable us to manage the complexity of CAR-T projects effectively. We offer comprehensive services, from process and analytical development to clinical and commercial manufacturing.

What Customers Say

User 18***3

The Creative Biolabs team has a strong professional background and is able to customize the design according to our project requirements. At the same time, they are able to stand in the perspective of the client to consider the project situation, and their services have provided a lot of help for the success of our project.

Creative Biolabs is committed to advancing the development and manufacturing of CAR-T cell therapies. Our comprehensive CDMO services, state-of-the-art technology and unwavering commitment to quality ensure that our customers can bring innovative therapies to market efficiently and reliably.